# Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies

> **NIH NIH R01** · DUKE UNIVERSITY · 2024 · $387,128

## Abstract

Project Summary/Abstract
Myeloid malignancies are a group of often lethal cancers that derive from cells of the myeloid lineage of the
hematopoietic system and include acute myeloid leukemia (AML) and diverse myelodysplastic syndromes
(MDS) and myeloproliferative neoplasms (MPN), the latter of which include chronic myelogenous leukemia
(CML) and primary myelofibrosis. AML, the most common acute leukemia in adults, is responsible for
significant cancer-related mortality, with a five-year survival rate of 28.9%. Although recent advances in
genomics and other areas have significantly improved our understanding of the molecular events that underlie
AML pathogenesis, these advances have yet to translate to significant improvements in the overall outcomes
of patients with the disease, which have remained relatively unchanged over the last 40 years.
In notable contrast to the scenario for AML, outcomes in patients diagnosed with a different leukemia, chronic
lymphocytic leukemia (CLL), have been transformed in recent decades by drugs that target proteins such as
Bruton’s tyrosine kinase (BTK), PI3Kd, and CD20, whose expression and function are unique to the B cell
lineage from which these cancers arise. These agents, which exhibit narrow side effect profiles, can thus be
used chronically, alone or in combination with one another or additional agents to yield very long term disease
control. Similar advances in the targeting of proteins with lineage-specific expression profiles and
dependencies have led to substantial improvements in the treatment of patients with breast, prostate, and
neural crest-derived tumors.
Recently, we discovered that the PI3Kg holoenzyme, comprised of the catalytic p110g and regulatory p101
subunits, is a profound regulator of AKT signaling, survival, and chemosensitivity in AML whose expression is
restricted to hematopoietic cells, and particularly those of the myeloid lineage. Thus, targeting this critical
signaling node leads to marked antitumor effects in AML cell lines, patient-derived cultures, and PDX models
without the systemic toxicities historically associated with pan- or a/b isoform-specific PI3K inhibition. In this
proposal, we describe studies to comprehensively characterize the expression and function of PI3Kg across all
major AML subtypes as well the normal cell types of the hematopoietic system. Further, we propose to define
the fundamental mechanisms governing PI3Kg expression in AML, then evaluate the therapeutic efficacy and
safety of targeting this signaling axis in gold standard xenograft, humanized mouse, and genetically
engineered mouse models of AML. Together, these studies will define a novel, lineage-restricted signaling axis
regulating survival in myeloid malignancies whose selective targeting may add substantially to the therapeutic
armamentarium in AML.

## Key facts

- **NIH application ID:** 10772021
- **Project number:** 5R01CA266389-03
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Kris C. Wood
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $387,128
- **Award type:** 5
- **Project period:** 2022-04-01 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10772021

## Citation

> US National Institutes of Health, RePORTER application 10772021, Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies (5R01CA266389-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10772021. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*